ResMed (RMD) Earnings Date & Reports
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea... Show more
RMD is expected to report earnings to rise 1.05% to $2.89 per share on July 30
ResMed Inc. (RMD) Third Quarter Fiscal Year 2026 Earnings Recap: EPS Surges 21% on Margin Expansion
Key Takeaways
- Revenue reached $1.43 billion, up 11% year-over-year on a headline basis and 8% in constant currency (cc), slightly beating consensus estimates of $1.42 billion.
- Non-GAAP earnings per share (EPS) climbed 21% to $2.86, surpassing expectations around $2.80.
- Non-GAAP gross margin expanded 290 basis points to 62.8%, driven by manufacturing efficiencies and lower component costs.
- Masks and accessories revenue grew 15% globally, with international markets up 20%.
- Operating cash flow hit $554 million, supporting ongoing investments in digital health.
- Shares traded relatively flat post-earnings, closing slightly higher at $212.16 on April 30.
Earnings Context and Why It Matters
As a leader in sleep apnea devices, masks, and digital health solutions, ResMed's quarterly results offer critical insights into demand for home-based respiratory care amid rising awareness of sleep disorders. The third quarter of fiscal year 2026 (ended March 31, 2026) builds on prior momentum, with consistent double-digit revenue growth reflecting robust global adoption of products like CPAP (continuous positive airway pressure) machines. For investors, these figures signal operational resilience, margin discipline, and potential in scaling SaaS (software-as-a-service) platforms for care management, especially as healthcare shifts toward outpatient settings. Missing broader FY2026 guidance keeps focus on execution into year-end.
ResMed reported total revenue of $1,431.4 million for the third quarter, a 11% increase from $1,291.7 million in the prior-year period, or 8% excluding currency impacts. This topped analyst consensus of approximately $1.42 billion. Sleep and Breathing Health revenue rose 11% to $1,260.5 million, fueled by 15% growth in masks and accessories ($524.8 million globally) and 9% in devices ($735.7 million). Residential Care Software (SaaS) grew 6% to $170.9 million.
Profitability shone brightly, with non-GAAP EPS (adjusted for certain one-time items) at $2.86, up 21% year-over-year from $2.37 and ahead of $2.79-$2.81 estimates. GAAP EPS (under Generally Accepted Accounting Principles) was $2.74, up 10%. Non-GAAP gross margin improved to 62.8% from 59.9%, thanks to cost savings in supply chain and manufacturing. Non-GAAP operating income increased 18% to $524.8 million.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
ResMed shares ended April 30 at $212.16, up marginally from $211.93 the prior day, reflecting a muted reaction to the mixed beat on EPS and revenue alongside impressive margins. After-hours trading showed stability with a slight 0.03% uptick, as investors weighed strong profitability against conservative commentary on investments in digital health and acquisitions like VirtuOx. Sentiment remains positive on long-term growth in sleep health but cautious ahead of fiscal year-end.
Forward Outlook and Key Factors to Monitor
Following these results, investors should track ResMed's execution in the fourth quarter ending June 30, 2026, as the company emphasized continued investment in innovation without issuing specific guidance. Momentum in masks and devices, particularly internationally, suggests sustained demand for sleep apnea solutions.
Key areas include gross margin trends, with efficiencies from supply chain optimizations potentially offsetting rising marketing and R&D spend for new products like the AirTouch F30i mask. Digital health scaling via SaaS platforms and partnerships will be pivotal for recurring revenue growth.
Broader dynamics such as global access to care, healthcare-at-home shifts, and potential impacts from economic pressures on elective procedures warrant attention. Upcoming catalysts may include fiscal year-end results in late July and updates on digital ecosystem expansions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a manufacturer of devices for evaluation and treatment of sleep disorders
Industry PharmaceuticalsOther